SCHEMBL3015699

SCHEMBL3015699

Cc1cc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.35
TSHR P16473 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
HTT P42858 2/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MAPT P10636 2/20 0.34
GAA P10253 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
RECQL P46063 1/20 0.34
ALOX15 P16050 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
DNM1L O00429 2/20 0.34
CNR1 P21554 2/20 0.33
CNR2 P34972 1/20 0.33
RAB9A P51151 1/20 0.33
ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019037 0.93 GAA (0.36) EPHX2HTTALDH1A1MAPTGAA
SCHEMBL3011124 0.93 SMN1; SMN2 (0.37) TSHRNPSR1HTTMEN1POLB
SCHEMBL3015218 0.90 CTSS (0.41) MEN1KMT2AMAPTSMN1; SMN2DNM1L
SCHEMBL3017811 0.90 TSHR (0.36) TSHRNPSR1HTTMEN1POLB
SCHEMBL3007436 0.90 MAPK1 (0.39) TSHRHTTPOLBKMT2AALDH1A1
SCHEMBL3021241 0.89 CHRM5 (0.35) EPHX2MEN1KMT2ADNM1LCNR1
SCHEMBL3015436 0.89 EPHX2 (0.40) EPHX2TSHRMEN1KMT2AALDH1A1
SCHEMBL2998623 0.88 MAPT (0.37) EPHX2TSHRNPSR1HTTMEN1
SCHEMBL3011591 0.88 ACHE (0.36) TSHRNPSR1HTTMEN1POLB
SCHEMBL3018177 0.88 MAPT (0.44) TSHRNPSR1HTTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA EPHX2 4409/4885TSHR 3320/4885NPSR1 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.